This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05100/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB05100/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05100/identifier/pubchem-substance/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05100/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05100
rdf:type
n3:Drug
n3:description
AG3340 is a synthetic hydroxamic acid derivative with potential antineoplastic activity. AG3340 inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, AG3340 crosses the blood-brain barrier.
n3:generalReferences
# Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10415735 # Deryugina EI, Ratnikov BI, Strongin AY: Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Int J Cancer. 2003 May 1;104(5):533-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12594807 # Scatena R: Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs. 2000 Sep;9(9):2159-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060800
n3:group
investigational
n3:halfLife
2-5 hours
n3:indication
Investigated for use/treatment in brain cancer, lung cancer, and prostate cancer.
owl:sameAs
n6:DB05100
dcterms:title
AG3340
adms:identifier
n9:2312492 n10:3855971 n11:DB05100 n12:3050430
n3:synonym
Prinomastat
n3:IUPAC-Name
n4:271B63AC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B63B2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B63B1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B63AE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B63AF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B63B0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B63AA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B63A8-363D-11E5-9242-09173F13E4C5 n4:271B63AB-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B63A9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B63B8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B63B9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B63B3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B63B4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B63B6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B63B5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B63B7-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
192329-42-3
n3:category
n3:Bioavailability
n4:271B63BE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B63C0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B63C1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B63BD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B63BC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B63BF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B63AD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B63BA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B63BB-363D-11E5-9242-09173F13E4C5